Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Thermo Fisher Scientific Adds Digital PCR to Genetic Analysis Capabilities


WALTHAM, Mass., Sept. 20, 2021 /PRNewswire/ -- Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, today launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

The QuantStudio Absolute Q  provides an industry-best dPCR platform accelerating innovation in cancer research and more.

dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays.

The dPCR technology that powers the QuantStudio Absolute Q solution is already in use by biotech companies and academic institutions for longitudinal monitoring of cancer-driving mutations in liquid biopsy, precise quantification of gene inserts for cell therapy development, and copy number variation studies for earlier identification of genetic conditions in newborns.

"These early adopters of dPCR technologies have faced limitations, including error-prone operation, imprecision and poor turnaround times," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "For our customers, the QuantStudio Absolute Q Digital PCR System overcomes these limitations and provides an industry-best dPCR platform to enable accelerated innovation in cancer research, rare diseases and much more."

Philip Lee, Chief Technology Officer, Senti Biosciences said "Accurate measurement of genetic biomarkers is critical to Senti Biosciences' gene circuit technology. We adopted this novel solution for its fast and simple workflow, which makes a significant difference in generating consistent and accurate data quickly.  It was straightforward to implement, and new users can generate the data that we need with ease."

Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. Hands-on time is just five minutes, minimizing the risk of user error.

For more information, please visit www.thermofisher.com/digitalpcr.

* For research use only.  Not for use in diagnostic procedures

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada 
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

SOURCE Thermo Fisher Scientific


These press releases may also interest you

at 11:10
The "Global Microcarrier Market Size By Product, By Application, By End-User, By Geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering. The global microcarrier market was valued at USD 1,271.04 Million in 2019 and...

at 11:05
Researchers from the University of Dundee and Promega Corporation have shown how a "three-headed hydra" significantly improves efficacy in targeted protein degradation. This discovery opens new possibilities in a field that is revolutionizing drug...

at 11:05
The Drug Enforcement Agency (DEA) National Prescription Drug Take-Back Day is on Saturday, October 23, 2021.  From 10:00 AM to 2:00 PM, the DEA will provide the public with a free and convenient opportunity to dispose of unwanted, unused, and expired...

at 11:00
The most recent data on the evolution of COVID-19, in the last 24 hours, in Québec show: 428 new cases, bringing the total number of people infected to 421,357; 405,126 people have recovered; 3 new deaths, for a total of 11,458 deaths;...

at 11:00
Technavio's latest offering, Laboratory Centrifuge Market report provides a detailed analysis on the competitive scenario, the pre- and post-COVID-19 impact on businesses, and the market growth across various regions....

at 11:00
NuProbe scientists and collaborators recently announced research demonstrating the accurate quantitation of somatic mutations below 0.01% variant allele frequency (VAF). By integrating molecular barcoding technology with the Blocker Displacement...



News published on 20 september 2021 at 08:00 and distributed by: